Literature DB >> 27392937

Prophylactic L-arginine and ibuprofen delay the development of tactile allodynia and suppress spinal miR-155 in a rat model of diabetic neuropathy.

Ghada M El-Lithy1, Wesam M El-Bakly1, Marwa Matboli2, Hadwa A Abd-Alkhalek3, Somaia I Masoud1, May Hamza4.   

Abstract

Diabetic neuropathy (DN) is a common complication of diabetes mellitus that is hardly reversible at the late stages. Since treatment of neuropathic pain is predominantly symptomatic, a prophylactic measure would be useful. Both ibuprofen and L-arginine exert antiallodynic effects on chronic constriction injury (CCI)-induced cold allodynia. Furthermore, ibuprofen is effective in CCI-induced mechanical allodynia. The aim of the study was to assess the antiallodynic effect of prophylactic ibuprofen and L-arginine in streptozotocin-induced DN in rats and to further investigate the role of spinal miR-155 and nitric oxide (NO) in this effect. Tactile allodynia was assessed weekly by von Frey filaments. Oral daily administration of ibuprofen, L-arginine and their combination, for 4 weeks starting 1 week after streptozotocin injection (ie, before the development of tactile allodynia), resulted in a significant decrease of tactile allodynia compared with the control diabetic group. This was evident in the fifth week of the experiment. The 3 treatments prevented the decrease in muscle fiber diameter and epidermal thickness, seen in the control diabetic group. Furthermore, ibuprofen, L-arginine and their combination prevented the increase in the spinal NO level and miRNA-155, seen in the control diabetic group. In conclusion, both ibuprofen and L-arginine delayed the development of behavioral and histologic changes of DN, with concomitant suppression of spinal miR-155 and NO level. L-arginine being tolerable may be useful prophylactically in diabetic patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27392937     DOI: 10.1016/j.trsl.2016.06.005

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  12 in total

Review 1.  Role of miRNAs in diabetic neuropathy: mechanisms and possible interventions.

Authors:  Prabhsimran Kaur; Sushil Kotru; Sandeep Singh; Anjana Munshi
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.590

2.  L-Arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats by normalizing plasma nitric oxide concentration and increasing plasma agmatine concentration.

Authors:  Lusliany J Rondón; M C Farges; N Davin; B Sion; A M Privat; M P Vasson; A Eschalier; C Courteix
Journal:  Eur J Nutr       Date:  2017-07-19       Impact factor: 5.614

Review 3.  Current insight into the roles of microRNA in vitiligo.

Authors:  Shili Yan; Jingpei Shi; Dongjie Sun; Lechun Lyu
Journal:  Mol Biol Rep       Date:  2020-02-21       Impact factor: 2.316

4.  Celecoxib ameliorates diabetic neuropathy by decreasing apoptosis and oxidative stress in dorsal root ganglion neurons via the miR-155/COX-2 axis.

Authors:  Xiaoliang Cheng; Ling Zhao; Tingyu Ke; Xi Wang; Lijun Cao; Shuyan Liu; Jie He; Wei Rong
Journal:  Exp Ther Med       Date:  2021-06-02       Impact factor: 2.447

5.  Inhibition of spinal 15-LOX-1 attenuates TLR4-dependent, nonsteroidal anti-inflammatory drug-unresponsive hyperalgesia in male rats.

Authors:  Ann M Gregus; Matthew W Buczynski; Darren S Dumlao; Paul C Norris; Ganesha Rai; Anton Simeonov; David J Maloney; Ajit Jadhav; Qinghao Xu; Spencer C Wei; Bethany L Fitzsimmons; Edward A Dennis; Tony L Yaksh
Journal:  Pain       Date:  2018-12       Impact factor: 7.926

6.  The role of miR-190a-5p contributes to diabetic neuropathic pain via targeting SLC17A6.

Authors:  Di Yang; Qinyan Yang; Xinchuan Wei; Yang Liu; Ding Ma; Jiaceng Li; Yongling Wan; Yao Luo
Journal:  J Pain Res       Date:  2017-10-04       Impact factor: 3.133

7.  MicroRNA-182 Alleviates Neuropathic Pain by Regulating Nav1.7 Following Spared Nerve Injury in Rats.

Authors:  Weihua Cai; Qingzan Zhao; Jinping Shao; Jingjing Zhang; Lei Li; Xiuhua Ren; Songxue Su; Qian Bai; Ming Li; Xuemei Chen; Jian Wang; Jing Cao; Weidong Zang
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

8.  microRNA-155 inhibition restores Fibroblast Growth Factor 7 expression in diabetic skin and decreases wound inflammation.

Authors:  João Moura; Anja Sørensen; Ermelindo C Leal; Rikke Svendsen; Lina Carvalho; Rie Juul Willemoes; Per Trolle Jørgensen; Håvard Jenssen; Jesper Wengel; Louise Torp Dalgaard; Eugénia Carvalho
Journal:  Sci Rep       Date:  2019-04-09       Impact factor: 4.379

9.  MicroRNA-155-5p promotes neuroinflammation and central sensitization via inhibiting SIRT1 in a nitroglycerin-induced chronic migraine mouse model.

Authors:  Qianwen Wen; Yunfeng Wang; Qi Pan; Ruimin Tian; Dunke Zhang; Guangcheng Qin; Jiying Zhou; Lixue Chen
Journal:  J Neuroinflammation       Date:  2021-12-10       Impact factor: 8.322

Review 10.  Insights into the Role of MicroRNAs in the Onset and Development of Diabetic Neuropathy.

Authors:  Raffaele Simeoli; Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.